Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.
Studies have demonstrated that active-specific immunotherapy has potential for controlling mammary tumor progression. Human chorionic gonadotropin (hCG) is expressed and extremely sensitive, easily detectable and highly correlated with breast cancer. We developed a gene vaccine using a plasmid vector to deliver the six copies of 10-amino acid residues of beta-hCG 109-118 and beta hCG C-terminal 37-amino acid (CTP37). BALB/c female mice were immunized with a combination of pCR-HBc-X6-betahCGCTP37 DNA vaccine and HSP-X6-betahCGCTP37 protein vaccine. pCR-HBc-X6-betahCGCTP37 DNA vaccine were injected intramuscularly three times, on days -46,-25 and -11 and HSP-X6-betahCGCTP37 protein were applied two times, 21 and 14 days before tumor cell challenge. We assessed a combined DNA and protein vaccine for its effect of against murine EMT6 mammary tumor cells. In this study, animals vaccinated DNA vaccination boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65 induced higher avidity antibodies and effectively inhibited the growth of tumor, compared with treatment using DNA alone or BCG priming HSP-X6-betahCGCTP37 protein boosting. The data presented demonstrate that improve immunogenicity of DNA vaccination by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65, which should prove useful in the development of new DNA vaccine against growth factors for cancer immunotherapy.
Yi
He
H
Minigene Pharmacy Laboratory, Biopharmaceutical College, China Pharmaceutical University, Tongjia Xiang 24, Nanjing 210009, PR China.
Rong
Yan
Y
Yankai
Zhang
Z
Wentao
Liu
L
Hongxia
Zhou
Z
Jie
Wu
W
Rongyue
Cao
C
Taiming
Li
L
Jingjing
Liu
L
D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D001426:Bacterial Proteins / Q000737:chemistry*; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000008:administration & dosage / Q000737:chemistry; D045744:Cell Line, Tumor; D018834:Chaperonin 60; D018833:Chaperonins / Q000737:chemistry*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009161:Mycobacterium / Q000737:chemistry; D017434:Protein Structure, Tertiary; D012091:Repetitive Sequences, Nucleic Acid; D014611:Vaccination / Q000379:methods / Q000592:standards; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D000912:Antibodies, Neoplasm; D001426:Bacterial Proteins; D019496:Cancer Vaccines; D002352:Carrier Proteins; D018834:Chaperonin 60; D006063:Chorionic Gonadotropin; D019444:Vaccines, DNA; C074119:heat-shock protein 65, Mycobacterium; D018833:Chaperonins